Show simple item record

dc.contributor.authorCojocaru, E
dc.contributor.authorPalahepitiva Gamage, G
dc.contributor.authorButler, J
dc.contributor.authorBarton, DP
dc.contributor.authorThway, K
dc.contributor.authorFisher, C
dc.contributor.authorMessiou, C
dc.contributor.authorMiah, AB
dc.contributor.authorZaidi, S
dc.contributor.authorGennatas, S
dc.contributor.authorBenson, C
dc.contributor.authorHuang, P
dc.contributor.authorJones, RL
dc.date.accessioned2021-03-31T08:45:13Z
dc.date.available2021-03-31T08:45:13Z
dc.date.issued2021-03-01
dc.identifier.citationGynecologic oncology reports, 2021, 36 pp. 100737 - ?
dc.identifier.issn2352-5789
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4470
dc.identifier.eissn2352-5789
dc.identifier.doi10.1016/j.gore.2021.100737
dc.description.abstractOvarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients being alive at 5 years. Only a few cases have been published in the literature and there is very limited knowledge on the clinical behaviour and optimal management of these tumours. We have performed a retrospective analysis of a prospectively maintained database to identify all primary ovarian leiomyosarcoma diagnosed and treated at the Royal Marsden NHS Foundation Trust between 1998 and 2020. Sixteen patients were identified from our database and fifteen were eligible for the analysis. Twelve patients presented with localized disease and underwent initial surgery and three patients had metastatic disease at presentation. Recurrence-free survival post-surgery was 16 months. Eight patients received first-line chemotherapy and four patients received second-line chemotherapy. Two patients had indolent metastatic disease and benefited from local therapies only. The median overall survival in the metastatic setting in our cohort was 51 months, which is consistent with previously published cases. Primary ovarian leiomyosarcoma is an extremely rare malignancy with a poor prognosis. This study is the largest case series of primary ovarian leiomyosarcoma published to date, providing clinically important information regarding survival and metastatic rate as well as treatment outcomes in the metastatic setting.
dc.formatElectronic-eCollection
dc.format.extent100737 - ?
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleClinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.
dc.typeJournal Article
dcterms.dateAccepted2021-02-15
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.gore.2021.100737
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGynecologic oncology reports
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusAccepted
pubs.volume36
pubs.embargo.termsNot known
icr.researchteamMolecular and Systems Oncology
icr.researchteamTargeted Therapy
icr.researchteamMolecular and Systems Oncology
icr.researchteamTargeted Therapy
dc.contributor.icrauthorCojocaru, Elena
dc.contributor.icrauthorHuang, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0